Interestingly, our data demonstrate that exogenous cholesterol, as an agonist of ERRα, does not significantly alter the abundances of metabolites corresponding to the glutaminolysis, PPP, and OCM pathways in TNBC or ER+ breast cancer cells. This evidence concerns the gene ESRRA and breast carcinoma.